Foghorn Therapeutics Experiences 5.9% Increase in Short Interest in 2023
March 10, 2023
Trending News ☀️
Foghorn Therapeutics ($NASDAQ:FHTX) Inc. experienced a notable increase in short interest in 2023. Over the last month, the amount of short interest rose by 5.9%. This increase was largely attributed to investors becoming more interested in Foghorn’s innovative offerings. Foghorn provides a range of therapies for patients with genetic and rare diseases.
The company is well-known for its drug discovery platform, which uses gene editing and gene modulation technology to develop treatments tailored to individual patient’s needs. This cutting-edge approach has garnered much attention from both investors and the medical community. With this newfound interest, Foghorn is positioned to continue to develop groundbreaking treatments and provide life-changing therapies to those in need.
Price History
This news has been largely positive, and the company’s stock opened at $5.5 on Tuesday, where it closed at the same price, down by 0.2% from the prior closing price. This is indicative of a generally favorable outlook for Foghorn Therapeutics, which may be due to their commitment to creating innovative treatments for diseases like cancer and neurological disorders. With the increase in short interest, it is possible that the company may continue to experience growth in the coming years. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Foghorn Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 15.76 | -109.14 | -684.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Foghorn Therapeutics. More…
| Operations | Investing | Financing |
| 234.42 | -228.14 | 23.49 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Foghorn Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 433.93 | 409.61 | 0.58 |
Key Ratios Snapshot
Some of the financial key ratios for Foghorn Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -689.9% |
| FCF Margin | ROE | ROA |
| 1481.2% | -188.9% | -15.7% |
Analysis
At GoodWhale, we’re committed to helping investors make informed decisions. That’s why we’ve compiled detailed financial data on FOGHORN THERAPEUTICS to allow for a comprehensive analysis. After running our risk rating on the company, we’ve come to the conclusion that FOGHORN THERAPEUTICS is a medium risk investment. We’ve also detected 2 risk warnings in the company’s balance sheet and cashflow statement. If you want to get into more details about what these risks are, you can register and log on to GoodWhale.com and have access to all the data we’ve collected. With our automated analysis tools, you can get a better understanding of FOGHORN THERAPEUTICS’s financial health – and make an informed decision about investing in the company. More…
Peers
With each of these companies striving to develop innovative treatments and therapies, the race to stay ahead of the competition is ever-present.
– Omega Therapeutics Inc ($NASDAQ:OMGA)
Omega Therapeutics Inc is a biopharmaceutical company based in San Francisco that focuses on the research and development of novel therapies to address unmet needs in immunology. As of 2023, Omega Therapeutics has a market capitalization of 335.71M, which reflects the company’s current value in the public markets. Additionally, Omega Therapeutics has a Return on Equity of -48.06%, which indicates that the shareholders’ investment in the company has resulted in a net loss in the past year.
– TME Pharma NV ($BER:0N6A)
TME Pharma NV is a biopharmaceutical company based in Belgium that is focused on developing innovative treatments for chronic and rare diseases. As of 2023, the company has a market cap of 1.59M. TME Pharma’s Return on Equity (ROE) is -271.38%, which suggests that the company has struggled to generate profits from its investments. Despite this, the company is developing a strong pipeline of promising new treatments and could well see its market cap increase in the future.
– Shattuck Labs Inc ($NASDAQ:STTK)
Shattuck Labs Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel immunotherapies for the treatment of cancer and other diseases. It has a market cap of 122.25M as of 2023 and a negative Return on Equity (ROE) of -34.39%. The market cap indicates that the company is valued at over one hundred million dollars, while its negative ROE suggests that it has not had much success generating profits from its operations. Nevertheless, Shattuck Labs Inc remains dedicated to its mission of discovering and developing novel immunotherapies for cancer and other diseases.
Summary
Foghorn Therapeutics Inc. has seen a 5.9% increase in short interest in 2023, signaling investor confidence in the company’s future performance. Analysts have been generally positive about the prospects of Foghorn Therapeutics, citing their innovative technology and the potential to revolutionize how drugs are developed and administered. Furthermore, there have been multiple partnerships and acquisitions that have further strengthened the company’s position. Despite the current market volatility, investors remain optimistic about Foghorn’s potential, making it a favorable investment choice for those looking for long-term growth.
